Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is -30.07% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation.
Limited quarterly history available
ROA needs at least three reported quarters before a meaningful chart is shown.
RETURN ON ASSETS (ROA)
-30.07%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+6.73%
vs the sector median at left
Seaport Therapeutics, Inc. Common Stock
Market Cap
$942.38M
Return on Assets (ROA)
-30.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$938.35M
Return on Assets (ROA)
-50.49%
TTM Avg
-30.32%
3Y Avg
-31.10%
5Y Avg
-27.11%
Market Cap
$935.90M
Return on Assets (ROA)
-39.67%
TTM Avg
-22.62%
3Y Avg
-34.56%
5Y Avg
-34.56%
Market Cap
$953.94M
Return on Assets (ROA)
-72.50%
TTM Avg
-45.97%
3Y Avg
-37.50%
5Y Avg
-37.52%
Market Cap
$930.32M
Return on Assets (ROA)
-45.94%
TTM Avg
-39.23%
3Y Avg
-37.58%
5Y Avg
-117.41%
Market Cap
$969.98M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
Market Cap
$912.83M
Return on Assets (ROA)
4.06%
TTM Avg
3.72%
3Y Avg
3.23%
5Y Avg
2.82%
Market Cap
$976.29M
Return on Assets (ROA)
1.18%
TTM Avg
-2.92%
3Y Avg
-0.56%
5Y Avg
1.87%
Market Cap
$899.69M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $942.38M | -30.07% | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $938.35M | -50.49% | -30.32% | -31.10% | -27.11% |
| CeriBell, Inc. (CBLL)vs › | $935.90M | -39.67% | -22.62% | -34.56% | -34.56% |
| Savara Inc. (SVRA)vs › | $953.94M | -72.50% | -45.97% | -37.50% | -37.52% |
| MoonLake Immunotherapeutics (MLTX)vs › | $930.32M | -45.94% | -39.23% | -37.58% | -117.41% |
| Aktis Oncology, Inc. (AKTS)vs › | $969.98M | -13.12% | -18.77% | -18.48% | -18.48% |
| HealthStream, Inc. (HSTM)vs › | $912.83M | 4.06% | 3.72% | 3.23% | 2.82% |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | 1.18% | -2.92% | -0.56% | 1.87% |
| Bioventus Inc. (BVS)vs › | $899.69M | 8.09% | -0.64% | -8.03% | -4.54% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | -23.69% | -98.11% | -69.18% | -69.18% |
ROA
-30.1%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.07% |
